ClinicalTrials.gg
Active, not recruitingNCT04966559Updated Mar 21, 2024

Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent Acute Pancreatitis

A Phase 2/3 interventional study of Placebo treatment and Naldemedine 0.2 MG Oral Tablet in Pancreatitis, Acute, sponsored by Asbjørn Mohr Drewes. Active, not recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by Asbjørn Mohr Drewes · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 7 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Pancreatitis with a site in Denmark — 3 open to participants now, 4 under way, 1 of them phase 3. Pancreatitis · Denmark.

Started
2022
with 2 others
Phase 2/3
2 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
2 of 11
Asbjørn Mohr Drewes

Among the 11 studies in Pancreatitis with a site in Denmark, this one is one of 3 that started in 2022, is one of 2 in phase 2/3, and was the 9th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

3 of the 11 studies in Pancreatitis with a site in Denmark are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Pancreatitis with a site in Denmark, or all of them as a file.
02

Study summary

This study will investigate the effect of a peripheral acting opioid antagonist (PAMORA) on the disease course of patients with recurrent acute inflammation of the pancreas (acute pancreatitis). The study will be conducted by treating outpatients suffering from recurrent acute pancreatitis with a PAMORA (naldemedine) for 12 months.

Read the detailed description

In this study, the effects of a peripheral acting µ-opioid receptor antagonist (PAMORA) on disease recurrence and progression in patients with recurrent acute pancreatitis (RAP) will be investigated. Patients with RAP will be administered 0,2 mg naldemedine orally daily or matching placebo. This medication is defined as the investigational product. Naldemedine is approved by the European Medical Agency for treatment of opioid-induced constipation. This PAMORA have not previously been investigated in patients with pancreatitis. The dose regimes for this study will be according to label. It has previously been shown, in patients with opioid-induced obstipation and healthy subjects, that opioid antagonism incl. PAMORA treatment increases gut motility, relaxes gastrointestinal sphincters, increases the intestinal water content and improves the immune response, without affecting analgesia. The affinity of PAMORAs to the µ-opioid receptors is much stronger than opioid analgesics. Therefore, they as antagonists have the potential to counteract the harmful effects of opioids on the gut mucosa, bacterial translocation and inflammation despite the high levels of exogenous opioids present in patients with pancreatitis. PAMORAs do not cross the blood-brain barrier and consequently do not interfere with analgesia or other central effects of opioids.

It is hypothesized that treatment with the PAMORA naldemedine will antagonize the harmful effects of opioids without reducing analgesia in patients with RAP and hence reduce disease severity and improve clinical outcomes. If successful, this study will for the first time document the effects of a targeted pharmacotherapy in RAP with the potential benefit of improved patient outcomes.

03

Conditions studied

  • Pancreatitis, Acute

Browse trials for

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed before any study specific procedures
  • Able to read and understand Danish or Swedish (depending on site)
  • Male or female age between 18 and 74 years
  • At least one attack of non-biliary AP (as defined by the revised Atlanta criteria) within the last 12 months and at least two attacks within 5 years
  • Clinically stable at time of inclusion
  • The researcher believes that the participant understands what the study entails, is capable of following instructions, can attend when needed, and is expected to complete the study
  • The investigator will ensure that fertile female participants have a negative pregnancy test before treatment initiation and use during the study period. The following methods of contraception, if properly used, are generally considered reliable: oral contraceptives, patch contraceptives, injection contraceptives, vaginal contraceptive ring, intrauterine device, surgical sterilization (bilateral tubal ligation), vasectomized partner, double barrier (condom and pessary), or sexual abstinence. Methods of contraception will be documented in the source documents

Exclusion criteria

Exclusion Criteria:

  • Known allergy towards study medication
  • Known or suspected major stenosis or perforation of the intestines
  • Known or suspected abdominal cancer (incl. intestine, pancreas and the biliary tree)
  • Pre-existing renal insufficiency (defined as habitual below 45)
  • Female participants that are lactating
  • Severe pre-existing comorbidities (assessed by investigator upon inclusion)
  • Attack of AP requiring admission within two weeks prior to inclusion
  • Gallstone etiology of RAP (MRCP or endoscopic ultrasound excluding biliary etiology of AP must be available prior to enrolment as part of the protocol)
  • Treatment with potent -inhibitors (ketoconazol, itraconzol, ritonavir) or P-gp inhibitors (e.g. cyclosporine).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Placebo comparator
    Placebo treatment

    Film-coated matched placebo-tablets consisting of: Core: Mannitol, USP/Ph. Eur./JP Croscarmellose Sodium, NF/Ph. Eur./JP Magnesium Stearate, NF/Ph. Eur./JP Coating: Opadry Yellow Purified Water, USP/EP

    Drug: Placebo treatment

  • Active comparator
    Naldemedine treatment

    Film-coated matched active-tablets consisting of: Core: Naldemedine Tosylate (0,2 mg) Mannitol, USP/Ph. Eur./JP Croscarmellose Sodium, NF/Ph. Eur./JP Magnesium Stearate, NF/Ph. Eur./JP Coating: Opadry Yellow Purified Water, USP/EP

    Drug: Naldemedine 0.2 MG Oral Tablet

Interventions

  • DrugPlacebo treatment

    Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.

  • DrugNaldemedineStudies of NaldemedineNaldemedine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.

06

What researchers measure

Primary outcomes

  1. Number of AP attacks verified by the Atlanta Criteria

    The primary outcome is defined as time to (recurrent) AP attack(s) verified by the Atlanta Criteria between the naldemedine group and the placebo group. The Atlanta Criteria is the current gold standard for the diagnosis of AP attack, and it requires a minimum of two out three of the following features: (i) Abdominal pain typical for acute pancreatitis featuring acute onset of a severe and persistent epigastric pain radiating to the back (ii) Serum amylase levels \> three times greater than the normal upper limit (iii) Findings of pancreatic inflammation in contrast-enhanced computed tomography, magnetic resonance imaging or transabdominal ultrasonography.

    Time frame: Observation period starts from day of randomization and ends after a minimum of 6 months and a maximum of 12 months

Secondary outcomes

  1. Pain intensity

    Individual difference between subgroups in number and severity of pain attacks (without fulfilling AP criteria) assessed by pain diary and modified Brief Pain Inventory short form on visual analogue scale from 0-10 (0 is no pain and 10 is worst pain). For each attack, participants will be asked to fill in the pain attack diary and the modified Brief Pain Inventory short form once.

    Time frame: Observation period starts from day of randomization and ends after a minimum of 6 months and a maximum of 12 months

  2. Gut function (BSFS)

    Difference between subgroups in gut function assessed by The Bristol Stool Form Scale for assessment of stool frequency as well as stool consistency (scale from 1-7, where 1 is firmeste and 7 is softest).

    Time frame: Day of randomization and at follow up visit after a minimum of 6 months and a maximum of 12 months

  3. Gut function (GSRS)

    Difference between subgroups in gut function assessed by Gastrointestinal Symptom Rating Scale which is a disease-specific instrument of 15 items combined into five symptom clusters depicting reflux, abdominal pain, indigestion, diarrhea and constipation. The GSRS has a seven-point graded Likert-type scale, where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.

    Time frame: Day of randomization and at follow up visit after a minimum of 6 months and a maximum of 12 months

  4. Health resource utilization

    Difference in health resource utilization (measured in frequency and type of health services used (e.g. blood sample, MRI etc.) that can be converted into danish currency for economic analyses) between subgroups based on service codes (all services have unique service codes stored digitally).

    Time frame: Observation period starts from day of randomization and ends after a minimum of 6 months and a maximum of 12 months

  5. Pancreatic volume

    Difference in pancreatic volume measured in cubic centimeters cm\^3 between subgroups, measured by MRI.

    Time frame: Day of randomization and at follow up visit after a minimum of 6 months and a maximum of 12 months

  6. Exocrine pancreatic function

    Difference between subgroups in exocrine pancreatic function assessed by fecal-elastase (µg/g) test.

    Time frame: Day of randomization and at follow up visit after a minimum of 6 months and a maximum of 12 months

  7. Endocrine pancreatic function

    Difference between subgroups in endocrine pancreatic function assessed by hemoglobinA1c (HbA1c) (mmol/mol) test.

    Time frame: Day of randomization and at follow up visit after a minimum of 6 months and a maximum of 12 months

  8. Quality of life (EORTC QLQ-C30)

    Difference between subgroups in quality of life assessed by EORTC QLQ-C30 questionnaire. The questionnaire has been validated for assessment of quality of life in patients with chronic pancreatitis and is composed of single-item measures and multi-item scales with scores ranging from 0 to 100 after linear transformation of the raw score. A high score for a functional scale represents a high level of functioning, as does a high score for the global health status, while a high score for the symptom items represents a high level of symptomatology.

    Time frame: Day of randomization and at follow up visit after a minimum of 6 months and a maximum of 12 months

  9. Impression of change

    Difference between subgroups in Patient Global Impression of Change. PGIC is a seven-point rating scale for self-report of a patient's experienced efficacy of treatment on their symptoms.

    Time frame: Day of randomization and at follow up visit after a minimum of 6 months and a maximum of 12 months

07

Study locations

5 sites
  • Mech-Sense, Department of Medical Gastroenterology, Aalborg University Hospital
    Aalborg, Jutland 9000, Denmark
  • Digestive Disease Center K, Bispebjerg University Hospital
    Bispebjerg, Denmark
  • Gastrounit, Hvidovre University Hospital
    Hvidovre, Denmark
  • Odense Pancreas Center
    Svendborg, Denmark
  • Karolinska University Hospital
    Stockholm, Solna (l1:00) SE-171 76, Sweden
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2022 (actual). Primary completion is estimated for Mar 2024, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2021
First posted
Jul 19, 2021
StartActual
Jan 12, 2022
Primary completionEst.
Mar 30, 2024
CompletionEst.
Jun 1, 2024
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04966559
Lead sponsor
Asbjørn Mohr Drewes
Collaborators
Odense University Hospital, Hvidovre University Hospital, University Hospital Bispebjerg and Frederiksberg, Karolinska University Hospital
Responsible party
Asbjørn Mohr Drewes (Professor, Chief Physician, MD, PhD, DMSc, Aalborg University Hospital) — Sponsor-investigator
First posted
Jul 19, 2021
Start date
Jan 12, 2022
Primary completion
Mar 30, 2024 (estimated)
Completion
Jun 1, 2024 (estimated)
Last update
Mar 21, 2024

Study contacts

Asbjørn M. Drewes, Professor
principal investigator · Aalborg University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naldemedine

Start the discussion